By Ian Walker 
 

Sanofi S.A. and GlaxoSmithKline PLC said Wednesday that they have reached an agreement with the U.K. government to supply up to 60 million doses of a Covid-19 vaccine, subject to final contract.

The French and U.K. pharmaceutical companies said the vaccine candidate is based on Sanofi's technology that produces an influenza vaccine as well as GSK's pandemic adjuvant technology.

Sanofi is leading clinical development and registration of the Covid-19 vaccine and plans a Phase 1, 2 study in September, followed by a Phase 3 study by the end of the year. If data proves positive, regulatory approval could be received in the first half of next year, it said.

 

Write to Ian Walker at ian.walker@wsj.com

 

(END) Dow Jones Newswires

July 29, 2020 01:39 ET (05:39 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.